Published: Sun, January 14, 2018
Business | By Tara Barton

Amicus Therapeutics (FOLD) Receives "Buy" Rating from Cowen

Venbio Select Advisor Llc acquired 2.75 million shares as Amicus Therapeutics Inc (Call) (FOLD)'s stock rose 23.92%.

The stock exchanged hands with a volume of 4.42 million shares compared to its standard daily volume. About 483,305 shares traded or 9.57% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since January 12, 2017 and is uptrending. It has underperformed by 16.70% the S&P500. Currently, the stock has a 1 Year Price Target of $19.21. The firm's revenue for the quarter was up 419.0% compared to the same quarter a year ago. Bremer Trust National Association who had been investing in Pultegroup Inc for a number of months, seems to be bullish on the $9.90B market cap company.

The stock decreased 6.37% or $0.95 during the last trading session, reaching $13.96. About 1.48M shares traded. It has outperformed by 13.38% the S&P500.

Investors sentiment increased to 2.33 in 2017 Q3. Its up 0.19, from 1.15 in 2017Q2.

Nationwide Fund Advisors lifted its position in Amicus Therapeutics, Inc. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. (NASDAQ:NTAP). Ing Groep Nv, Netherlands-based fund reported 9,469 shares. $570,132 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 5,878 shares.

Fundsmith Llp holds 7.54% of its portfolio in Waters Corporation for 4.36 million shares. Mutual Of America Cap Management Limited Liability Corporation accumulated 78,400 shares. The Virginia-based Thompson Davis & Inc has invested 0.01% in Amicus Therapeutics, Inc. Franklin Resources holds 0.02% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 1.47 million shares. Federated Invsts Pa stated it has 0.01% in Amicus Therapeutics, Inc. Advisor Partners Ltd Liability Corporation invested in 3,216 shares. 111,027 were reported by Metropolitan Life Insur. The firm is having analyst recommendation of 1.70 on scale of 1 to 5. Therefore 65% are positive. Amicus Therapeutics had 20 analyst reports since August 18, 2015 according to SRatingsIntel. 7,000 Amicus Therapeutics, Inc. Cowen & Co maintained the stock with "Buy" rating in Monday, August 7 report. The company presently has an average rating of Buy and a consensus target price of $18.31. The rating was maintained by Jefferies on Friday, March 11 with "Buy". JPMorgan Chase & Co. restated an "overweight" rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Standpoint Research has "Sell" rating and $125 target. The stock has "Outperform" rating by Robert W. Baird on Wednesday, July 12. (NASDAQ:FOLD) earned "Buy" rating by Leerink Swann on Monday, August 31. The stock has "Buy" rating by Cowen & Co on Monday, August 7. On Thursday, October 12 Do Hung sold $715,360 worth of Amicus Therapeutics, Inc.

Varnika Kundu stalking case: Barala gets bail from HC
While accepting his bail plea, Justice Lisa Gill warned Vikas not to try to influence the trial, going on in a Chandigarh court.

Since October 12, 2017, it had 0 buys, and 14 sales for $10.19 million activity. RAAB MICHAEL had sold 10,000 shares worth $142,534. On Tuesday, October 17 the insider Crowley John F sold $1.06M. (NASDAQ:FOLD). D E Shaw holds 0.1% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Baird William D III on Tuesday, January 2. Barth Jay had sold 5,000 shares worth $71,268 on Thursday, October 12.

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. (NASDAQ:FOLD) on Tuesday, March 8 to "Buy" rating. During the same quarter last year, the firm posted ($0.33) earnings per share. research analysts predict that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Looking further out, over the past twelve months, Amicus Therapeutics, Inc.'s stock was 181.22% and 10.32% over the last quarter and 22.43% for the past six months.

Valued now at $13.96, the vast majority of Wall Street analysts continue to say it's worth buying. Therefore 73% are positive. Cognex Corporation had 35 analyst reports since August 4, 2015 according to SRatingsIntel. As per Wednesday, November 15, the company rating was maintained by Barclays Capital. RBC Capital Markets has "Buy" rating and $28.0 target. Leerink Swann restated an "outperform" rating and issued a $17.00 price target (down from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. The rating was downgraded by J.P. Morgan on Wednesday, November 1 to "Hold". Janney Capital upgraded Amicus Therapeutics, Inc. The rating was upgraded by Barclays Capital on Wednesday, April 6 to "Equal-Weight".

Investors sentiment increased to 1.34 in Q3 2017. Its down 1.07, from 2.62 in 2017Q2. Cowen & Co maintained the shares of FOLD in report on Sunday, June 25 with "Buy" rating. 55 funds opened positions while 111 raised stakes. 125.34 million shares or 324.34% more from 29.54 million shares in 2017Q2 were reported. Vanguard Group Inc Inc invested in 0.01% or 13.28M shares. J Goldman & Lp reported 203,500 shares or 0.15% of all its holdings. Cornerstone has invested 0.03% of its portfolio in Dollar General Corporation (NYSE:DG). 2 were reported by Oakworth Capital. About 5.00 million shares traded or 5.97% up from the average. Millennium Management Ltd Liability Corp owns 271,491 shares. Tekla Capital Mgmt Ltd stated it has 275,494 shares. Crestpoint Management Limited Liability reported 0.25% of its portfolio in Alaska Air Group, Inc. 1,902 were accumulated by Guardian Cap L P. Hays Advisory Llc has invested 0.09% of its portfolio in The Boeing Company (NYSE:BA). Credit Suisse Ag holds 0.02% or 451,628 shares in its portfolio.

Like this: